Completed PHASE3 INTERVENTIONAL 2-arm NCT02968368

Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease (AEGIS-CKD)

A Phase 3, Randomized, Placebo Controlled, Prospective, Multicenter Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease

Sponsor: Shield Therapeutics

Conditions Iron-Deficiency Anemia Renal Insufficiency, Chronic

Interventions Ferric maltol Placebo

Updated 13 times since 2017 Last updated: Oct 5, 2020 Started: Dec 1, 2016 Primary completion: Jan 18, 2018 Completion: Oct 10, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Iron-Deficiency Anemia and Renal Insufficiency, Chronic and is currently completed. Shield Therapeutics leads this study, which shows 13 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

13 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 8 earlier versions

Dec 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2020 — Dec 2020 [monthly]

Completed PHASE3

Status: Unknown Status → Completed
Nov 2019 — Jun 2020 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jun 2018 — Nov 2019 [monthly]

Recruiting PHASE3
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE3
May 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Feb 2017 — May 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shield Therapeutics

Data source: Shield Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asheville, United States , Bethlehem, United States , Charlotte, United States , Coral Springs, United States , Denver, United States , Edgewater, United States , El Paso, United States , Hampton, United States , Knoxville, United States , La Mesa, United States and 16 more locations